TY  - JOUR
AU  - Denkinger, Claudia M
AU  - Janssen, Maike
AU  - Schäkel, Ulrike
AU  - Gall, Julia
AU  - Leo, Albrecht
AU  - Stelmach, Patrick
AU  - Weber, Stefan F
AU  - Krisam, Johannes
AU  - Baumann, Lukas
AU  - Stermann, Jacek
AU  - Merle, Uta
AU  - Weigand, Markus A
AU  - Nusshag, Christian
AU  - Bullinger, Lars
AU  - Schrezenmeier, Jens-Florian
AU  - Bornhäuser, Martin
AU  - Alakel, Nael
AU  - Witzke, Oliver
AU  - Wolf, Timo
AU  - Vehreschild, Maria J G T
AU  - Schmiedel, Stefan
AU  - Addo, Marylyn M
AU  - Herth, Felix
AU  - Kreuter, Michael
AU  - Tepasse, Phil-Robin
AU  - Hertenstein, Bernd
AU  - Hänel, Mathias
AU  - Morgner, Anke
AU  - Kiehl, Michael
AU  - Hopfer, Olaf
AU  - Wattad, Mohammad-Amen
AU  - Schimanski, Carl C
AU  - Celik, Cihan
AU  - Pohle, Thorsten
AU  - Ruhe, Matthias
AU  - Kern, Winfried V
AU  - Schmitt, Anita
AU  - Lorenz, Hanns-Martin
AU  - Souto-Carneiro, Margarida
AU  - Gaeddert, Mary
AU  - Halama, Niels
AU  - Meuer, Stefan
AU  - Kräusslich, Hans-Georg
AU  - Müller, Barbara
AU  - Schnitzler, Paul
AU  - Parthé, Sylvia
AU  - Bartenschlager, Ralf
AU  - Gronkowski, Martina
AU  - Klemmer, Jennifer
AU  - Schmitt, Michael
AU  - Dreger, Peter
AU  - Kriegsmann, Katharina
AU  - Schlenk, Richard F
AU  - Müller-Tidow, Carsten
TI  - Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial.
JO  - Nature cancer
VL  - 4
IS  - 1
SN  - 2662-1347
CY  - London
PB  - Nature Research
M1  - DKFZ-2022-03217
SP  - 96-107
PY  - 2023
N1  - 2023 Jan;4(1):96-107 / HI-TRON
AB  - Patients with cancer are at high risk of severe coronavirus disease 2019 (COVID-19), with high morbidity and mortality. Furthermore, impaired humoral response renders severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines less effective and treatment options are scarce. Randomized trials using convalescent plasma are missing for high-risk patients. Here, we performed a randomized, open-label, multicenter trial ( https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001632-10/DE ) in hospitalized patients with severe COVID-19 (n = 134) within four risk groups ((1) cancer (n = 56); (2) immunosuppression (n = 16); (3) laboratory-based risk factors (n = 36); and (4) advanced age (n = 26)) randomized to standard of care (control arm) or standard of care plus convalescent/vaccinated anti-SARS-CoV-2 plasma (plasma arm). No serious adverse events were observed related to the plasma treatment. Clinical improvement as the primary outcome was assessed using a seven-point ordinal scale. Secondary outcomes were time to discharge and overall survival. For the four groups combined, those receiving plasma did not improve clinically compared with those in the control arm (hazard ratio (HR) = 1.29; P = 0.205). However, patients with cancer experienced a shortened median time to improvement (HR = 2.50; P = 0.003) and superior survival with plasma treatment versus the control arm (HR = 0.28; P = 0.042). Neutralizing antibody activity increased in the plasma cohort but not in the control cohort of patients with cancer (P = 0.001). Taken together, convalescent/vaccinated plasma may improve COVID-19 outcomes in patients with cancer who are unable to intrinsically generate an adequate immune response.
LB  - PUB:(DE-HGF)16
C6  - pmid:36581734
DO  - DOI:10.1038/s43018-022-00503-w
UR  - https://inrepo02.dkfz.de/record/186515
ER  -